The potential role of bisphosphonates in prostate cancer (Q35081743)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	The potential role of bisphosphonates in prostate cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

The potential role of bisphosphonates in prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Oades GM

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Coxon J

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Colston KW

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Prostate Cancer and Prostatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

264-272

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Changing trends in prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Prostate cancer. Primary hormonal treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Overview of bisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Parathyroid hormone related protein and hypercalcaemia in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Bone resorption by osteoclasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Regulation of the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Farnesyltransferase inhibitors: potential role in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Bisphosphonates induce apoptosis in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Pathophysiologic interactions in skeletal metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Concomitant i.v. and oral clodronate in the relief of bone pain – a double-blind placebo-controlled study in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Treatment of painful prostatic bone metastases with oral etidronate disodium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Pathophysiology of bone pain: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Therapeutic approaches to bone diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

21 January 2018

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Retention of etidronate in human, dog, and rat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonates: Mechanisms of Action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of action of bisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast cancer cells interact with osteoblasts to support osteoclast formation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Generalised increase in bone resorption in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Morphometric evidence for bone resorption and replacement in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical spectrum of hypocalcaemia associated with bone metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperparathyroidism in metastases of prostatic carcinoma: a biochemical, hormonal and histomorphometric study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Pamidronate administration improves the secondary hyperparathyroidism due to “Bone hunger syndrome” in a patient with osteoblastic metastases from prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500607

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.PCAN.4500607

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35081743&oldid=2197225196"